Skip to NavigationSkip to content

keytruda

Prostate Cancer ‘super responders’ could live for two more years on Keytruda

Men with advanced prostate cancer, who have exhausted all treatment options, could use the immunotherapy Keytruda (pembrolizumab) to live for another two years or more.

A major clinical trial showed that a small proportion of men were ‘super responders’ and were alive and well even after the trial had ended, despite having had a very poor prognosis before treatment.

Europe approves Keytruda for first-line head and neck squamous cell carcinoma, as a monotherapy or combo

MSD’s top-selling immunotherapy Keytruda (pembrolizumab) has secured another approval from the European Commission, this time in the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in patients whose tumours express PD-L1.

Phase 3 data supporting the application demonstrated that Keytruda significantly improved overall survival compared with standard treatment (cetuximab with carboplatin or cisplatin plus 5-FU), either as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy.

Keytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor market, report reveals

MSD’s Keytruda (pembrolizumab) overtook Bristol-Myers Squibb’s (BMS) blockbuster drug Opdivo (nivolumab) in total sales in the third quarter of 2019 to emerge as leader in the global immune checkpoint inhibitor market, according to a new report from GlobalData.

According to the findings, MSD’s drug saw a 62% growth in revenue compared to Q3 2018 to reach $3.1 million. Over the same period, Opdivo experienced sales growth of just 1%, generating $1.8 million

Scotland approves first-line NHS use of MSD's Keytruda combo for advanced non-small cell lung cancer

The Scottish Medicines Consortium (SMC) has announced its decision to accept MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy on the NHS in Scotland for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients.

The decision affects patients whose tumours express PD-L1 with a <50% tumour proportion score (TPS), or in when it has not been possible to evaluate PD-L1 TPS, but excludes patients whose tumours have the specific gene mutations EGFR or ALK.

US, Canada and Australia simultaneously fast-track Keytruda/Lenvima combo for endometrial cancer

The FDA has acted under a new initiative in collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, conducting simultaneous review in all three countries to award accelerated approval to the combination of Keytruda (pembrolizumab)and Eisai's Lenvima (lenvatinib) for the treatment of advanced endometrial carcinoma.

Project Orbis, as the initiative is known, “provides a framework for concurrent submission and review of oncology drugs among its international partners”, potentially facilitating earlier access to medicines by overcoming delays in regu

MSD's Keytruda approved for first-line lung cancer use on NHS Scotland

MSD and lung cancer patients will be celebrating the news that the pharma giant’s immunotherapy Keytruda (pembrolizumab) has been accepted by the Scottish Medicines Consortium (SMC), in combination with carboplatin and paclitaxel chemotherapy, for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC).

The decision means that Keytruda becomes the first drug approved in Scotland in the first-line treatment of this indication; patients will be able to access the drug on the NHS, but only those whose tumours express programmed death ligand 1 (PD-L1) with a

Keytruda scores EU approval in combination with Inlyta for first-line advanced renal cell carcinoma

The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the tyrosine kinase inhibitor Inlyta (axitinib) in the first-line treatment of advanced renal cell carcinoma (RCC).

The ruling was made on the back of Phase 3 data confirming that the combination of Keytruda and Inlyta reduced the risk of death by 47% in RCC patients compared to Pfizer’s Sutent (sunitinib), while also presenting benefit in both progression-free survival and objective response rate.

Medicare will cover CAR-T therapies in United States

Medicare will cover the cost of Novartis’ and Gilead’s CAR-T therapies Kymriah and Yescarta, the US Centers for Medicare and Medicaid services (CMS) said.

Medicare, the federal government’s health plan for over-65s has said it will cover the FDA approved CAR-T therapies Kymriah and Yescarta when provided in healthcare facilities that have programmes in place to track patient outcomes, known as REMS.

Keytruda/chemo combo recommended for first-line lung cancer via Cancer Drugs Fund

MSD’s Keytruda (pembrolizumab) has secured recommendation from NICE for inclusion on the Cancer Drugs Fund (CDF) in combination with chemotherapy in the first-line treatment of untreated metastatic squamous non-small cell lung cancer (NSCLC), it has emerged.

The final appraisal determination marks the first for a immunotherapy/chemotherapy combo in this indication regardless of PD-L1 expression.

MSD's Keytruda combo hits primary endpoint at Phase 3 in triple-negative breast cancer

MSD’s blockbuster anti-PD-L1 immunotherapy Keytruda (pembrolizumab) has impressed in newly released Phase 3 data; the company announced that, when combined with chemotherapy, the drug met one of its primary endpoints in the treatment of triple-negative breast cancer (TNBC).

Findings derived from a study of 1,174 TNBC patients and analysed by the independent Data Monitoring Committee demonstrated that Keytruda generated a “statistically significant improvement” in rates of pathological complete response (pCR) compared to chemo alone, regardless of PD-L1 status, as determined by a la

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches